News & Events
August 9, 2023
C-Path’s Duchenne Regulatory Science Consortium and Duchenne Data Foundation Announce Collaboration to Advance Solutions for Duchenne Muscular DystrophyTUCSON, Ariz. and VEENENDAAL, Netherlands, August 9, 2023 — Critical Path Institute’s (C-Path) Duchenne Regulatory Science Consortium (D-RSC) and the Duchenne Data Foundation (DDF) are excited to announce a joint collaboration aimed at advancing research and improving healthcare for individuals with Duchenne muscular dystrophy (DMD) and other dystrophinopathies (conditions linked to mutations in the DMD......
May 3, 2022
RDCA-DAP Responsive Curation Levels – Dr. Ramona Walls
This was presented as part of the RDCA-DAP monthly steering committee meeting, on April 12, 2022. It describes the 8 curation levels used in RDCA-DAP, from raw ingest to mapped to OMOP CDM to fully integrated with ontologies. It explains how our responsive curation process supports FAIR data by sharing metadata as quickly as possible, to make data Findable, then successfully makes the data more Accessible, Interoperable, and Reusable based on demand for the data.
October 9, 2020
Webinar: Accelerating Drug Development for Rare Diseases through Data Sharing and Analysis (Sept.18, 2020)
Despite increasing numbers of drug targets and technologies, rare disease drug development is frequently slowed by the low numbers of patients and the lack of comprehensive quantitative characterization of diseases. Tucson’s Critical Path Institute (C-Path), along with the National Organization of Rare Disorders (NORD) and the FDA, have developed an integrated database and analytics hub called the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) to help accelerate clinical development, make it less expensive, and encourage new companies to develop treatments for rare diseases.
Presenters: Jane Larkindale, DPhil, Critical Path Institute, Executive Director Rare Disease Cures Accelerator-Data and Analytics Platform; Duchenne Regulatory Science Consortium
Vanessa Boulanger, MSc, National Organization for Rare Disorders, Director of Research Programs
Michelle Campbell, PhD, U.S. Food and Drug Administration, Sr. Clinical Analyst for Stakeholder Engagement and Clinical Outcomes, Division of Neurology Products
- September 25, 2020
- July 2, 2020